World Ovarian Cancer Day: Together We’re Stronger

Posted on May 5, 2015 by Paul Cacciatore

Each year, nearly a quarter of a million women around the world are diagnosed with ovarian cancer and the disease is responsible for 140,000 deaths annually. Statistics show that just 45% of women with ovarian cancer are likely to survive for five years compared with 89% of women with breast cancer. We ask that you join us on World Ovarian Cancer Day (May 8th) in the fight against the most lethal form of gynecologic cancer.

LEARN: World Ovarian Cancer Day — May 8, 2015

On May 8, 2015, the individuals from around the world are invited to join the global movement to raise awareness about ovarian cancer. This year the theme will celebrate the natural bond women have with each other, encouraging people to send in photos of celebratory bonding moments and to sign the awareness pledge located on the website (www.ovariancancerday.org) to spread the word about ovarian cancer for the third annual World Ovarian Cancer Day (WOCD).

Dr. Maya Soetoro-Ng, President Obama’s sister, speaks out about losing her mother to ovarian cancer.

“Now in its third year, World Ovarian Cancer Day has grown globally to over 78 organizations from 25 countries,” says Elisabeth Baugh, chair of the WOCD international organizing committee and CEO of Ovarian Cancer Canada. “In celebrating the unique bonds of women, we are acknowledging the strong drive they have to share and help each other. Without women, the world would not be. Joining together, our common voice symbolizes a global support group for the 250,000 women who will be diagnosed this year with ovarian cancer.”

Celebrate the women you love, trust, and are proud to know by helping to raise awareness about ovarian cancer and view a video of celebratory images to be released globally on May 8, World Ovarian Cancer Day.

“Our outreach has demonstrated the ability of this campaign to increase awareness of the disease and to connect people internationally with the resources available to educate others,” explained members of the Steering Committee, Calaneet Balas, CEO of the Ovarian Cancer National Alliance, Annwen Jones, Target Ovarian Cancer and Alison Amos, Ovarian Cancer Australia. “This year we want to put faces to that movement – faces of women who care about and support each other.”

In 2015, not only cancer organizations, but all interested groups who care about the health of women internationally are invited to register and partner with us. The pledge also engages individuals worldwide, empowering them with information about ovarian cancer and a quick and easy way to pass on the word about the disease.

All those who sign the World Ovarian Cancer Day pledge at www.ovariancancerday.org will receive an e-card on May 8 with ovarian cancer risk and symptom information. This card is to be passed along to at least five friends, who in turn will be encouraged to pass it along to their friends.

Each year, nearly a quarter of a million women around the world are diagnosed with ovarian cancer and the disease is responsible for 140,000 deaths annually. Statistics show that just 45% of women with ovarian cancer are likely to survive for five years compared with 89% of women with breast cancer. Women in developed and developing countries are similarly affected by ovarian cancer.

The recent disclosure by Angelina Jolie Pitt in a New York Times Op-Ed about prophylactic surgery to remove her fallopian tubes and ovaries because of a genetic predisposition for ovarian and breast cancer has put knowledge about your family history in the spotlight. Approximately 15%- 20% of cases of ovarian cancer are due to family history. This means having a close blood relation (mother, sister, daughter, grandmother, granddaughter, aunt or niece) on either your mother’s or your father’s side of the family who has had breast cancer before the age of 50 or ovarian cancer at any age.

In addition to sharing symptom and risk information, WOCD will also focus on prevention of ovarian cancer.

WOCD’s social media campaign includes the WOCD website (available in 4 languages: English, French, Portuguese and Spanish), Facebook, Twitter, YouTube and Pinterest. Activities in 2014 were highlighted in photos and through the pledge dissemination which reached over 15,000 people. This will continue to grow on May 8, including “lighting the world in teal” – the color that represents ovarian cancer.

World Ovarian Cancer Day has become a global movement in three short years. Uniting patient organizations globally, it has also sparked interest and involvement from healthcare professionals in countries around the world. This year, we celebrate the voice of women in making a difference as we unite and speak with one voice to raise awareness of ovarian cancer. Globally, rejoicing on our unique bond, we will ensure that no woman with ovarian cancer walks alone.

Please join us by signing the pledge form.

EDUCATE: Ovarian Cancer Facts:

Libby’s H*O*P*E* is dedicated to my 26-year old cousin, Elizabeth “Libby” Remick, who died from ovarian cancer in July 2008. Our mission is to educate ovarian cancer survivors and their families, as well as the general public, about ovarian cancer under the principle that “information is power.” The key to a significant reduction in deaths from ovarian cancer is early detection. Early detection is best achieved by having women listen to their bodies for the subtle, yet persistent, early warning signs & symptoms of the disease as described below. Together, we can raise money for a reliable early detection test, and ultimately a cure, for ovarian cancer.

Please take time to educate yourself with respect to the important ovarian cancer awareness facts provided below.

— Overview: Ovarian cancer causes more deaths than any other cancer of the female reproductive system. It is the fifth leading cancer cause of death among U.S. women.

— By the Numbers: In 2015, the American Cancer Society (ACS) estimates that there will be approximately 21,290 new ovarian cancer cases diagnosed in the U.S. ACS estimates that 14,180 U.S. women will die from the disease, or about 38 women per day. The loss of life is equivalent to 28 Boeing 747 jumbo jet crashes with no survivors every year.

— Early Warning Signs: Ovarian cancer is not a “silent” disease; it is a “subtle” disease. Recent studies indicate that some women may experience persistent, nonspecific symptoms, such as (i) bloating, (ii) pelvic or abdominal pain, (iii) difficulty eating or feeling full quickly, or (iv) urinary urgency or frequency. Women who experience such symptoms daily for more than a few weeks should seek prompt medical evaluation.

— Who’s Affected: Ovarian cancer can afflict adolescent, young adult, and mature women.

— Risk Reduction: Pregnancy, the long-term use of oral contraceptives, and tubal ligation reduce the risk of developing ovarian cancer. Recent research suggests that the most common form of ovarian cancer actually starts in the fallopian tubes. Any woman who is about to undergo gynecologic surgery may wish to discuss with her surgeon the possibility of having her fallopian tubes removed at that time.

— Importance of Family History: Women who have had breast cancer, or who have a paternal or maternal family history of breast cancer or ovarian cancer may have increased risk. Inherited mutations in BRCA1/BRCA2 genes increase risk. Women of Ashkenazi (Eastern European) Jewish ancestry are at higher risk for BRCA gene mutations. The incidence of ovarian ovarian cancer among Ashkenazi Jewish women is 1-in-40 versus 1-in-72 in the general population. Studies indicate that preventive surgery to remove the ovaries and fallopian tubes in women who possess a BRCA gene mutation decreases the risk of ovarian cancer.

— Genetic Couseling: If a woman has a family history of breast or ovarian cancer as described above, she may wish to seek genetic counselling. In fact, there is a recent shift in thinking that any woman with ovarian cancer should also seek genetic counselling as an important step for herself and other members of her family.

— Other Risk Factors: Other medical conditions associated with an increased ovarian cancer risk include pelvic inflammatory disease and Lynch syndrome. The use of hormonal replacement therapy has been shown to increase ovarian cancer risk. Tobacco smoking increases the risk of mucinous epithelial ovarian cancer. Heavier body weight may be associated with increased risk of ovarian cancer.

— Lack of a Reliable Early Screening Test: There is no reliable screening test for the detection of early stage ovarian cancer. Pelvic examination only occasionally detects ovarian cancer, generally when the disease is advanced. A Pap smear is used to detect cervical cancer, not ovarian cancer. However, the combination of a thorough pelvic exam, transvaginal ultrasound, and a blood test for the tumor marker CA125 may be offered to women who are at high risk of ovarian cancer and to women who have persistent, unexplained symptoms like those listed described above.

— Prognosis: If diagnosed at the localized stage, the 5-year ovarian cancer survival rate is 92%; however, only about 15% of all cases are detected at this stage, usually fortuitously during another medical procedure. The majority of cases (61%) are diagnosed at a distant stage, for which the 5-year survival rate is 27%.

— Survival Statistics: The 5-year and 10-year relative survival rates for all disease stages combined are only 45% and 35%, respectively. However, survival varies substantially by age; women younger than 65 are twice as likely to survive 5 years as women 65 and older (58% versus 27%).

Please help us to (i) spread the word about the early warning signs & symptoms of ovarian cancer, and (ii) raise money for ovarian cancer research. The life you save may be your own or that of a loved one.

FIGHT: The “Holy Trinity” of Major U.S. Ovarian Cancer Organizations

There are three major U.S. ovarian cancer organizations that are working to increase ovarian cancer awareness, and/or raise money to fight the disease. They are listed below. Please consider making a donation to one or more of these critically important nonprofit organizations.

Ovarian Cancer Research Fund

The Ovarian Cancer Research Fund (OCRF) is the largest independent organization in the U.S. that is dedicated exclusively to funding ovarian cancer research– and to finding a cure. Through its three research programs, OCRF funds many of the best researchers and the most innovative projects.

Since 1998, OCRF has awarded 63 leading medical centers 195 grants for ovarian cancer research: an investment totaling over $50 million. OCRF researchers are taking on ovarian cancer from many angles:

— Developing innovative strategies for early detection;

— Discovering genetic polymorphisms that increase risk for ovarian cancer;

— Understanding the underlying genetics and molecular biology of ovarian cancer;

— Identifying new, better targets for treatment;

— Determining how to super-charge a woman’s immune response to better fight ovarian cancer; and

— Deciphering how and why ovarian cancer spreads, and how to stop it.

You can click here to make a donation to OCRF through the Libby’s H*O*P*E*’s donation page.

Ovarian Cancer National Alliance

The Ovarian Cancer National Alliance (OCNA) is one of the foremost advocates for women with ovarian cancer in the U.S. To advance the interests of women with ovarian cancer, OCNA advocates at a national level for increases in research funding for the development of an early detection test, improved health care practices, and life-saving treatment protocols. OCNA also educates health care professionals and raises public awareness of the risks and symptoms of ovarian cancer.

To make a donation to OCNA, click here.

National Ovarian Cancer Coalition

The mission of the National Ovarian Cancer Coalition (NOCC) is to raise awareness and promote education about ovarian cancer. NOCC is committed to improving the survival rate and quality of life for women with ovarian cancer.

Through national programs and local Chapter initiatives, the NOCC’s goal is to make more people aware of the early symptoms of ovarian cancer. In addition, the NOCC provides information to assist the newly diagnosed patient, to provide hope to survivors, and to support caregivers.

To make a donation to NOCC, click here.

INSPIRE: Everyday Heroes in the Fight Against Ovarian Cancer.

Nearly 250,000 women are diagnosed with ovarian cancer every year around the world, and the disease also affects their families and friends. Please take time to visit the WOCD website and read the inspirational stories about survivors, volunteers, and family members who are overcoming ovarian cancer, as well as the endeavors people are taking on to raise awareness about the disease.

At Libby’s H*O*P*E*, we are amazed each and every day by the inspirational ovarian cancer survivors and family members that we hear about, correspond with, or meet. The stories below represent a small sample of incredible individuals who have successfully fought the disease, as well as those who are currently fighting the disease with courage and grace. There are also stories about women who have died from ovarian cancer, but contributed to ovarian cancer awareness in a unique and special way during life. In addition, there are stories about doctors, advocates, and other inspirational individuals who are clearly making a difference in the fight against the disease.

— “Bald is Beautiful,” March 20, 2008.

— “Patty Franchi Flaherty Loses Battle to Ovarian Cancer, But Deserves a Long Standing Ovation,” August 19, 2008.

— “Oscar Winner Kathy Bates Is an Inspirational Ovarian Cancer Survivor,” February 25, 2009.

— “Rare Form of Ovarian Cancer Not Getting Inspirational 13 Yr. Old Down; You Can Help!,” February 26, 2009.

— “Meet Laurey Masterton, 20-Year Ovarian Cancer Survivor Extraordinaire,” March 20, 2009.

— “The Rock Band ‘N.E.D.’: Their Medical Skills Save Many; Their Music Could Save Thousands,” March 29, 2009.

— “A Wish To Build A Dream On,” May 3, 2009.

— “Husband’s Love For Wife Inspires A 9,000 Mile Bike Trek To Raise Money For Ovarian Cancer Awareness & Cancer Prevention,” May 14, 2009.

— “Gloria Johns Was Told ‘Ovarian Cancer Patients Don’t Live Long Enough … To Have Support Groups;’ She Proved Otherwise,” June 5, 2009.

— “Vox Populi:* How Do Your Define “Tragedy?“, January 22, 2010.

— “Smile, Open Your Eyes, Love and Go On,” July 28, 2010.

— “PBS Documentary, ‘The Whisper: The Silent Crisis of Ovarian Cancer,'” September 21, 2010.

— “Determined Teen Loses Ovarian Cancer Battle, But Her Courage Inspires An Entire Community,” December 28, 2010.

— “Mrs. Australia Quest Finalist Veronica Cristovao Is Raising Ovarian Cancer Awareness ‘Down Under'”, February 28, 2011.

— “Whither Thou Goest, I Will Go …”, July 28, 2012.

— “Crowd Funding:” Paying Medical Bills With a Little Help From Your Friends (and Strangers Too!), January 17, 2013.

___________________________

For more information on World Ovarian Cancer Day visit: www.ovariancancerday.org

Facebook: www.facebook.com/WorldOvarianCancerDay

Twitter: @OvarianCancerDY

Pinterest: @OvarianCancerDY

Each participating country is linked through the dedicated website which has been established for World Ovarian Cancer Day. To find out more about activities in each country, please contact the local organization directly through the website at http://www.ovariancancerday.org/get-involved/

World Ovarian Cancer Day: One Voice for Every Woman

Posted on May 8, 2014 by Paul Cacciatore

Each year, nearly a quarter of a million women around the world are diagnosed with ovarian cancer and the disease is responsible for 140,000 deaths annually. Statistics show that just 45% of women with ovarian cancer are likely to survive for five years compared with 89% of women with breast cancer. We ask that you join us on World Ovarian Cancer Day (May 8th) in the fight against the most lethal form of gynecologic cancer.

LEARN: World Ovarian Cancer Day — May 8, 2014

On May 8, join the global movement to raise awareness about ovarian cancer by pledging to spread the word about the most serious gynecological cancer during the second annual World Ovarian Cancer Day (WOCD). The pledge to pass on the awareness message to at least five friends will bring to life this year’s theme One Voice for Every Woman.

“The number one objective of World Ovarian Cancer Day is to increase awareness of this disease and to connect people internationally with the resources available to educate others,” says Elisabeth Baugh, chair of the WOCD international organizing committee and CEO of Ovarian Cancer Canada. “In our inaugural year, 28 cancer organizations from 18 countries participated in getting the word out, largely through social media. In 2014, we are not only inviting cancer organizations, but all interested groups internationally to register and partner with us. With our pledge, we are also involving individuals worldwide, and empowering them with information about ovarian cancer and a quick and easy way to pass on the word about the disease.”

All of those who sign the World Ovarian Cancer Day pledge at www.ovariancancerday.org will receive an e-card on May 8 with ovarian cancer risk and symptom information. This card is to be passed along to at least five friends, who in turn will be encouraged to pass it along to their friends.

Each year, nearly a quarter of a million women around the world are diagnosed with ovarian cancer and the disease is responsible for 140,000 deaths annually. Statistics show that just 45% of women with ovarian cancer are likely to survive for five years compared with 89% of women with breast cancer. Women in developed and developing countries are similarly affected by ovarian cancer. There is no test for the early detection of ovarian cancer, a disease characterized around the world by a lack of awareness of symptoms and late stage diagnosis.

WOCD’s social media campaign includes the WOCD website, Facebook, Twitter and Pinterest. To help raise awareness and show international involvement in the inaugural year, partner organizations and individuals from many countries wore teal and posed for photos in front of well-known landmarks holding signs featuring the WOCD “world embrace” logo.

These photographs were shared around the world. Other activities included public awareness events at train and subway stations, and information tables and education sessions at hospitals and cancer centers. These activities will continue to grow on May 8, 2014 along with governmental proclamations and “lighting the world in teal” – the color that represents ovarian cancer. Committee members Annwen Jones, Chief Executive of Target Ovarian Cancer, and Alison Amos, CEO, Ovarian Cancer Australia agree this is a wonderful opportunity. “World Ovarian Cancer Day is an important day for ovarian cancer organizations and communities around the world to unite and speak with one voice to raise awareness of ovarian cancer. We’re proud to be involved with this global initiative and will be passing the awareness message out among those we work with. This activity supports our vision to save lives and ensure that no woman with ovarian cancer walks alone.” “For women living with the disease and their families and friends, World Ovarian Cancer Day has tremendous meaning,” says Baugh. “Through this important day, we will continue to build momentum and a sense of solidarity in the fight against ovarian cancer. Every woman is at some risk for ovarian cancer and awareness remains our best defence.”

EDUCATE: Ovarian Cancer Facts:

Please take time to educate yourself with respect to the important ovarian cancer awareness facts provided below.

–Ovarian cancer causes more deaths than any other cancer of the female reproductive system.

–In 2014, the American Cancer Society (ACS) estimates that there will be approximately 21,980 new ovarian cancer cases diagnosed in the U.S. ACS estimates that 14,270 U.S. women will die from the disease, or about 40 women per day. The loss of life is equivalent to 28 Boeing 747 jumbo jet crashes with no survivors every year.

–Ovarian cancer is not a “silent” disease; it is a “subtle” disease. Recent studies indicate that some women may experience persistent, nonspecific symptoms, such as (i) bloating, (ii) pelvic or abdominal pain, (iii) difficulty eating or feeling full quickly, or (iv) urinary urgency or frequency. Women who experience such symptoms daily for more than a few weeks should seek prompt medical evaluation.

–Ovarian cancer can afflict adolescent, young adult, and mature women.

–Pregnancy and the long-term use of oral contraceptives reduce the risk of developing ovarian cancer.

–Women who have had breast cancer, or who have a family history of breast cancer or ovarian cancer may have increased risk. Inherited mutations in BRCA1/BRCA2 genes increase risk. Women of Ashkenazi Jewish ancestry are at higher risk for BRCA gene mutations.

–There is no reliable screening test for the detection of early stage ovarian cancer. Pelvic examination only occasionally detects ovarian cancer, generally when the disease is advanced. A Pap smear is used to detect cervical cancer, not ovarian cancer. However, the combination of a thorough pelvic exam, transvaginal ultrasound, and a blood test for the tumor marker CA125 may be offered to women who are at high risk of ovarian cancer and to women who have persistent, unexplained symptoms like those listed above.

–If diagnosed at the localized stage, the 5-year ovarian cancer survival rate is 92%; however, only about 19% of all cases are detected at this stage, usually fortuitously during another medical procedure.

–The 10-year relative survival rate for all disease stages combined is only 38%.

Please help us spread the word about the early warning signs & symptoms of ovarian cancer and raise money for ovarian cancer research. The life you save may be your own or that of a loved one.

FIGHT: The “Holy Trinity” of Major U.S. Ovarian Cancer Organizations

There are three major U.S. ovarian cancer organizations that are working to increase ovarian cancer awareness, and/or raise money to fight the disease. They are listed below. Please consider making a donation to one of these critically important nonprofit organizations.

Ovarian Cancer Research Fund

— Developing innovative strategies for early detection;

— Discovering genetic polymorphisms that increase risk for ovarian cancer;

— Understanding the underlying genetics and molecular biology of ovarian cancer;

— Identifying new, better targets for treatment;

— Determining how to super-charge a woman’s immune response to better fight ovarian cancer; and

— Deciphering how and why ovarian cancer spreads, and how to stop it.

You can click here to make a donation to OCRF through the Libby’s H*O*P*E*’s donation page.

Ovarian Cancer National Alliance

To make a donation to OCNA, click here.

National Ovarian Cancer Coalition

To make a donation to NOCC, click here.

INSPIRE: Everyday Heroes in the Fight Against Ovarian Cancer.

Nearly a quarter million women are diagnosed with ovarian cancer every year around the world, and the disease also affects their families and friends. Please take time to visit the WOCD website and read inspirational stories about survivors, volunteers, and family members who are overcoming ovarian cancer, as well as the endeavors people are taking on to raise awareness about the disease.

— “Bald is Beautiful,” March 20, 2008.

— “Patty Franchi Flaherty Loses Battle to Ovarian Cancer, But Deserves a Long Standing Ovation,” August 19, 2008.

— “Oscar Winner Kathy Bates Is an Inspirational Ovarian Cancer Survivor,” February 25, 2009.

— “Rare Form of Ovarian Cancer Not Getting Inspirational 13 Yr. Old Down; You Can Help!,” February 26, 2009.

— “Meet Laurey Masterton, 20-Year Ovarian Cancer Survivor Extraordinaire,” March 20, 2009.

— “The Rock Band ‘N.E.D.’: Their Medical Skills Save Many; Their Music Could Save Thousands,” March 29, 2009.

— “A Wish To Build A Dream On,” May 3, 2009.

— “Husband’s Love For Wife Inspires A 9,000 Mile Bike Trek To Raise Money For Ovarian Cancer Awareness & Cancer Prevention,” May 14, 2009.

— “Gloria Johns Was Told ‘Ovarian Cancer Patients Don’t Live Long Enough … To Have Support Groups;’ She Proved Otherwise,” June 5, 2009.

— “Vox Populi:* How Do Your Define “Tragedy?“, January 22, 2010.

— “Smile, Open Your Eyes, Love and Go On,” July 28, 2010.

— “PBS Documentary, ‘The Whisper: The Silent Crisis of Ovarian Cancer,'” September 21, 2010.

— “Determined Teen Loses Ovarian Cancer Battle, But Her Courage Inspires An Entire Community,” December 28, 2010.

— “Mrs. Australia Quest Finalist Veronica Cristovao Is Raising Ovarian Cancer Awareness ‘Down Under'”, February 28, 2011.

— “Whither Thou Goest, I Will Go …”, July 28, 2012.

— “Crowd Funding:” Paying Medical Bills With a Little Help From Your Friends (and Strangers Too!), January 17, 2013.

___________________________

For more information on World Ovarian Cancer Day visit: www.ovariancancerday.org

Facebook: www.facebook.com/WorldOvarianCancerDay

Twitter: @OvarianCancerDY

Pinterest: @OvarianCancerDY

Inaugural World Ovarian Cancer Day: “World Embrace” to Learn, Educate, Fight & Inspire

Posted on May 8, 2013 by Paul Cacciatore

May 8th, 2013, is the first World Ovarian Cancer Day. On this day, 26 ovarian cancer organizations from 17 countries around the world will unite to educate their communities about ovarian cancer and its symptoms. For women living with the disease, and their families and friends, World Ovarian Cancer Day will build a sense of solidarity in the fight against ovarian cancer.

“LEARN:” Inaugural World Ovarian Cancer Day — May 8, 2013

Ovarian cancer has the lowest survival rate of all gynecologic cancers, and is characterized around the world by a lack of awareness of symptoms and late stage diagnosis.

Today, May 8th, 2013, is the first World Ovarian Cancer Day (WOCD). On this day, ovarian cancer organizations from around the world will unite to educate their communities about ovarian cancer and its symptoms. For women living with the disease, and their families and friends, World Ovarian Cancer Day will build a sense of solidarity in the fight against the disease.

In 2009, representatives from patient organizations working in ovarian cancer around the globe came together for the first time in a two day workshop, to discuss the common issues they faced in their work.

Unlike more common cancers, there are significant challenges as the disease has been largely overlooked and underfunded to this point. Symptoms which are similar to those of less serious illnesses, the absence of an early detection test, and the resulting late diagnosis and poor outcomes means there are few survivors of the disease to become advocates. This initial meeting galvanized the community to begin thinking about what could be accomplished on a global level to begin changing this situation.

By coming together since that first meeting, the group has considered the many gaps in understanding and managing the disease, building awareness in the general public about symptoms and the importance of family history, and increasing funding for research .The idea of a Global Awareness Day for Ovarian Cancer was put forward and embraced by all participants as an important joint international action creating a powerful momentum.

A brand for World Ovarian Cancer Day, “World Embrace,” was developed and launched to the international group in March 2013 in preparation for this important day.

“EDUCATE:” Ovarian Cancer Facts:

Please take time to educate yourself with respect to the important ovarian cancer awareness facts provided below.

–Ovarian cancer causes more deaths than any other cancer of the female reproductive system.

–In 2012, the American Cancer Society (ACS) estimates that there will be approximately 22,280 new ovarian cancer cases diagnosed in the U.S. ACS estimates that 15,550 U.S. women will die from the disease, or about 43 women per day. The loss of life is equivalent to 28 Boeing 747 jumbo jet crashes with no survivors every year.

–Ovarian cancer can afflict adolescent, young adult, and mature women.

–Pregnancy and the long-term use of oral contraceptives reduce the risk of developing ovarian cancer.

–The 10-year relative survival rate for all disease stages combined is only 38%.

Please help us spread the word about the early warning signs & symptoms of ovarian cancer and raise money for ovarian cancer research. The life you save may be your own or that of a loved one.

“FIGHT:” The “Holy Trinity” of Major U.S. Ovarian Cancer Organizations

There are three major U.S. ovarian cancer organizations that are working to increase ovarian cancer awareness, and/or raise money to fight the disease. They are listed below. Please consider making a donation to one of these critically important nonprofit organizations.

Ovarian Cancer Research Fund

— Developing innovative strategies for early detection;

— Discovering genetic polymorphisms that increase risk for ovarian cancer;

— Understanding the underlying genetics and molecular biology of ovarian cancer;

— Identifying new, better targets for treatment;

— Determining how to super-charge a woman’s immune response to better fight ovarian cancer; and

— Deciphering how and why ovarian cancer spreads, and how to stop it.

You can click here to make a donation to OCRF through the Libby’s H*O*P*E*’s donation page.

Ovarian Cancer National Alliance

To make a donation to OCNA, click here.

National Ovarian Cancer Coalition

To make a donation to NOCC, click here.

“INSPIRE:” Everyday Heroes in the Fight Against Ovarian Cancer.

— “Bald is Beautiful,” March 20, 2008.

— “Patty Franchi Flaherty Loses Battle to Ovarian Cancer, But Deserves a Long Standing Ovation,” August 19, 2008.

— “Oscar Winner Kathy Bates Is an Inspirational Ovarian Cancer Survivor,” February 25, 2009.

— “Rare Form of Ovarian Cancer Not Getting Inspirational 13 Yr. Old Down; You Can Help!,” February 26, 2009.

— “Meet Laurey Masterton, 20-Year Ovarian Cancer Survivor Extraordinaire,” March 20, 2009.

— “The Rock Band ‘N.E.D.’: Their Medical Skills Save Many; Their Music Could Save Thousands,” March 29, 2009.

— “A Wish To Build A Dream On,” May 3, 2009.

— “Husband’s Love For Wife Inspires A 9,000 Mile Bike Trek To Raise Money For Ovarian Cancer Awareness & Cancer Prevention,” May 14, 2009.

— “Gloria Johns Was Told ‘Ovarian Cancer Patients Don’t Live Long Enough … To Have Support Groups;’ She Proved Otherwise,” June 5, 2009.

— “Vox Populi:* How Do Your Define “Tragedy?“, January 22, 2010.

— “Smile, Open Your Eyes, Love and Go On,” July 28, 2010.

— “PBS Documentary, ‘The Whisper: The Silent Crisis of Ovarian Cancer,'” September 21, 2010.

— “Determined Teen Loses Ovarian Cancer Battle, But Her Courage Inspires An Entire Community,” December 28, 2010.

— “Mrs. Australia Quest Finalist Veronica Cristovao Is Raising Ovarian Cancer Awareness ‘Down Under'”, February 28, 2011.

— “Whither Thou Goest, I Will Go …”, July 28, 2012.

— “Crowd Funding:” Paying Medical Bills With a Little Help From Your Friends (and Strangers Too!), January 17, 2013.

___________________________

For more information on World Ovarian Cancer Day visit: www.ovariancancerday.org

Facebook: www.facebook.com/WorldOvarianCancerDay

Twitter: @OvarianCancerDY

Pinterest: @OvarianCancerDY

U.S. President Barack Obama Proclaims September 2011 As National Ovarian Cancer Awareness Month — What Should You Know?

Posted on September 1, 2011 by Paul Cacciatore

Today, U.S. President Barack Obama designated September 2010 as National Ovarian Cancer Awareness Month. During National Ovarian Cancer Awareness Month, Libby’s H*O*P*E*™ will honor the women who have lost their lives to the disease, support those who are currently battling the disease, and celebrate with those who have beaten the disease.

Today, U.S. President Barack Obama designated September 2010 as National Ovarian Cancer Awareness Month. During National Ovarian Cancer Awareness Month, Libby’s H*O*P*E*™ will honor the women who have lost their lives to the disease, support those who are currently battling the disease, and celebrate with those who have beaten the disease. This month, medical doctors, research scientists, and ovarian cancer advocates renew their commitment to develop a reliable early screening test, improve current treatments, discover new groundbreaking therapies, and ultimately, defeat the most lethal gynecologic cancer.

Let us begin this month with several important facts relating to ovarian cancer. Please take time to review these facts — they may save your life or that of a loved one.

Ovarian Cancer Facts

Ovarian cancer causes more deaths than any other cancer of the female reproductive system.

In 2011, the American Cancer Society (ACS) estimates that there will be approximately 21,990 new ovarian cancer cases diagnosed in the U.S. ACS estimates that 15,460 U.S. women will die from the disease, or about 42 women per day or 1 women every 30 minutes.

Ovarian cancer is not a “silent” disease; it is a “subtle” disease. Recent studies indicate that women with ovarian cancer are more like to experience four persistent, nonspecific symptoms as compared with women in the general population, such as (i) bloating, (ii) pelvic or abdominal pain, (iii) difficulty eating or feeling full quickly, or (iv) urinary urgency or frequency. Women who experience such symptoms daily for more than a few weeks should seek prompt medical evaluation.

Several other symptoms have been commonly reported by women with ovarian cancer. These symptoms include fatigue, indigestion, back pain, pain with intercourse, constipation and menstrual irregularities. However, these other symptoms are not as useful in identifying ovarian cancer because they are also found in equal frequency in women in the general population who do not have the disease.

Although the median age of a woman with ovarian cancer at initial diagnosis is 63, the disease cancer can afflict adolescent, young adult, and mature women. Ovarian cancer does not discriminate based upon age.

Pregnancy and the long-term use of oral contraceptives reduce the risk of developing ovarian cancer.

Women who have had breast cancer, or who have a family history of breast cancer or ovarian cancer may have increased risk. Inherited mutations in the BRCA1 or BRCA2 gene increase a woman’s lifetime risk of breast and ovarian cancer. Women of Ashkenazi (Eastern European) Jewish ancestry are at higher risk (1 out of 40) for inherited BRCA gene mutations.

There is no reliable screening test for the detection of early stage ovarian cancer. Pelvic examination only occasionally detects ovarian cancer, generally when the disease is advanced. A Pap smear cannot detect ovarian cancer. However, the combination of a thorough pelvic exam, transvaginal ultrasound, and a blood test for the tumor marker CA-125 may be offered to women who are at high risk of ovarian cancer and to women who have persistent, unexplained symptoms like those listed above.

If diagnosed at the localized stage, the 5-year ovarian cancer survival rate is 92%; however, only about 19% of all cases are detected at this stage, usually fortuitously during another medical procedure.

The 10-year relative survival rate for all disease stages combined is only 38%.

Help Spread the Word To “B-E-A-T” Ovarian Cancer

Please help us “B-E-A-T” ovarian cancer by spreading the word about the early warning signs & symptoms of the disease throughout the month of September.

B = bloating that is persistent and does not come and go

E = eating less and feeling fuller

A =abdominal or pelvic pain

T = trouble with urination (urgency or frequency)

Women who have these symptoms almost daily for more than a few weeks should see their doctor. Prompt medical evaluation may lead to detection at the earliest possible stage of the disease. Early stage diagnosis is associated with an improved prognosis.

Presidential Proclamation–National Ovarian Cancer Awareness Month

The White House

Office of the Press Secretary

For Immediate Release September 01, 2011

Presidential Proclamation–National Ovarian Cancer Awareness Month

NATIONAL OVARIAN CANCER AWARENESS MONTH, 2011

BY THE PRESIDENT OF THE UNITED STATES OF AMERICA

A PROCLAMATION

Ovarian cancer continues to have one of the highest mortality rates of any cancer, and it is a leading cause of cancer deaths among women in the United States. This month, we remember the mothers, sisters, and daughters we have lost to ovarian cancer, and we extend our support to those living with this disease. We also reaffirm our commitment to raising awareness about ovarian cancer, and to advancing our screening and treatment capabilities for the thousands of American women who will be diagnosed this year.

Ovarian cancer touches women of all backgrounds and ages. Because of a lack of early symptoms and effective screening tests, ovarian cancer is often not detected in time for successful interventions. It is crucial that women know how to recognize the warning signs of gynecological cancers and can detect the disease as early as possible. I encourage all women to learn about risk factors, including family history, and to discuss possible symptoms, including abdominal pain, with their doctor. Now, because of the Affordable Care Act, a wide range of preventive screenings are available to women without any copayments, deductibles, or coinsurance.

My Administration is committed to supporting the women, families, and professionals working to end this disease. The Centers for Disease Control and Prevention and the Department of Health and Human Services have started a campaign to educate women on cancers affecting reproductive organs. The National Cancer Institute is researching new ways to detect ovarian cancer, publishing a comprehensive study of the most aggressive types of ovarian cancer, and conducting clinical trials for new combinations of therapy. And this year, agencies across the Federal Government, from the National Institutes of Health to the Department of Defense, have committed to supporting ovarian cancer prevention and treatment research.

So many lives have been touched by ovarian cancer — from the women who fight this disease, to the families who join their loved ones in fighting their battle. In the memory of all the brave women who have lost their lives to ovarian cancer, and in support of generations of women to come, let us recommit to reaching a safer, healthier future for all our citizens.

NOW, THEREFORE, I, BARACK OBAMA, President of the United States of America, by virtue of the authority vested in me by the Constitution and the laws of the United States, do hereby proclaim September 2011 as National Ovarian Cancer Awareness Month. I call upon citizens, government agencies, organizations, health-care providers, and research institutions to raise ovarian cancer awareness and continue helping Americans live longer, healthier lives. And I urge women across the country to talk to their health-care providers and learn more about this disease.

IN WITNESS WHEREOF, I have hereunto set my hand this first day of September, in the year of our Lord two thousand eleven, and of the Independence of the United States of America the two hundred and thirty-sixth.

BARACK OBAMA

Sources:

Presidential Proclamation–National Ovarian Cancer Awareness Month 2011, issued September 1, 2011.

Ovarian Cancer Symptoms Consensus Statement, Originating Organizations — Gynecologic Cancer Foundation, Society of Gynecologic Oncology & American Cancer Society, January – April, 2007.

The Mirror: “What is the Meaning of Life?”

Posted on July 28, 2011 by Paul Cacciatore

Today marks the third anniversary of Libby’s passing, but we chose to celebrate her life instead.

Today marks the third anniversary of Libby’s passing, but we chose to celebrate her life instead.

As many of you know, the Libby’s H*O*P*E*™ website is dedicated to my 26-year old cousin, Elizabeth Remick, who lost her battle to the disease in 2008. Libby’s death was, in no uncertain terms, devastatingly tragic; however, her life was anything but. Her life and its inspiration were, and still remain, the driving force behind the website.

This morning, in reflecting about Libby’s life, I recalled the inspiration evoked by an essay entitled, “The Mirror.” This essay was written by the best-selling author Robert Fulghum, and published in his book of essays entitled, “It Was On Fire When I Lay Down On It.”

I like to think of the website as a “mirror” which is simply reflecting the light of Libby’s life — and now her spirit — to our readers, including the inspirational ovarian cancer survivors and their family members who visit us each day. As many of you know, it was Libby’s idea to share publicly the initial ovarian cancer information that I compiled for her benefit in 2007-2008; this information became the foundation for Libby H*O*P*E*™.

In this way, Libby possessed “ordinary grace,” a term coined by the author Kathleen Brehony in her book bearing the same title. As explained by Brehony in her book, ordinary grace does not live in sacred cathedrals or holy ashrams; rather, it lives in everyday heroes like Libby, who find a place in their life for compassion, generosity, forgiveness, love and simple kindness.

I hope that you enjoy The Mirror (reproduced in full below). More importantly, I hope that the essay inspires you to reflect your light — truth, knowledge and compassion — into the hearts of others who are experiencing difficult times in their lives. Libby is our light. And it is our greatest hope that you find the website an illuminating reflection of her light.

Libby, we love you, miss you, and will never forget you. Thank you for your life and eternal inspiration.

_________________________________

“The Mirror”

An essay written by Robert Fulghum

“Are There Any Questions?” An offer that comes at the end of college lectures and long meetings. Said when an audience is not only overdosed with information, but when there is no time left anyhow. At times like that you sure do have questions. Like “Can we leave now?” and “What the hell was this meeting for?” and “Where can I get a drink?”

The gesture is supposed to indicate openness on the part of the speaker, I suppose, but if in fact you do ask a question, both the speaker and audience will give you drop-dead looks. And some fool — some earnest idiot — always asks. And the speaker always answers. By repeating most of what he has already said.

But if there is a little time left and there is a little silence in response to the invitation, I usually ask the most important question of all: “What is the meaning of life?”

You never know, somebody may have the answer, and I’d really hate to miss it because I was too socially inhibited to ask. But when I ask, it’s usually taken as a kind of absurdist move — people laugh and nod and gather up their stuff and the meeting is dismissed on that ridiculous note.

Once, and only once, I asked that question and got a serious answer. One that is with me still.

First, I must tell you where this happened, because the place has a power of its own. In Greece again.

Near the village of Gonia on a rocky bay of the island of Crete, sits a Greek Orthodox monastery. Alongside it, on land donated by the monastery, is an institute dedicated to human understanding and peace, and especially to rapprochement between Germans and Cretans. An improbable task, given the bitter residue of wartime.

This site is important, because it overlooks the small airstrip at Maleme where Nazi paratroopers invaded Crete and were attacked by peasants wielding kitchen knives and hay scythes. The retribution was terrible. The populations of whole villages were lined up and shot for assaulting Hitler’s finest troops.

High above the institute is a cemetery with a single cross marking the mass grave of Cretan partisans. And across the bay on yet another hill is the regimented burial ground of the Nazi paratroopers. The memorials are so placed that all might see and never forget. Hate was the only weapon the Cretans had at the end, and it was a weapon many vowed never to give up. Never ever.

Against this heavy curtain of history, in this place where the stone of hatred is hard and thick, the existence of an institute devoted to healing the wounds of war is a fragile paradox. How has it come to be here? The answer is a man. Alexander Papaderos.

A doctor of philosophy, teacher, politician, resident of Athens but a son of this soil. At war’s end he came to believe that the Germans and the Cretans had much to give one another — much to learn from one another. That they had an example to set. For if they could forgive each other and construct a creative relationship, then any people could.

To make a lovely story short, Papaderos succeeded. The institute became a reality — a conference ground on the site of horror — and it was in fact a source of producive interaction between the two countries. Books have been written on the dreams that were realized by what people gave to people in this place.

By the time I came to the institute for a summer session, Alexander Papaderos had become a living legend. One look at him and you saw his strength and intensity — energy, physical power, courage, intelligence, passion, and vivacity radiated from this person. And to speak to him, to shake his hand, to be in a room with him when he spoke, was to experience his extraordinary electric humanity. Few men live up to their reputations when you get close. Alexander Papaderos was an exception.

At the last session on the last morning of a two-week seminar on Greek culture, led by intellectuals and experts in their fields who were recruited by Papaderos from across Greece, Papaderos rose from his chair at the back of the room and walked to the front, where he stood in the bright Greek sunlight of an open window and looked out. We followed his gaze across the bay to the iron cross marking the German cemetery.

He turned. And made the ritual gesture: “Are there any questions?”

Quiet quilted the room. These two weeks had generated enough questions for a lifetime, but for now there was only silence.

“No questions?” Papaderos swept the room with his eyes.

So. I asked.

“Dr. Papaderos, what is the meaning of life?”

The usual laughter followed, and people stirred to go.

Papaderos held up his hand and stilled the room and looked at me for a long time, asking with his eyes if I was serious and seeing from my eyes that I was.

“I will answer your question.”

Taking his wallet out of his hip pocket, he fished into a leather billfold and brought out a very small round mirror, about the size of a quarter.

And what he said went like this:

“When I was a small child, during the war, we were very poor and we lived in a remote village. One day, on the road, I found the broken pieces of a mirror. A German motorcycle had been wrecked in that place.

I tried to find all the pieces and put them together, but it was not possible, so I kept only the largest piece. This one. And by scratching it on a stone I made it round. I began to play with it as a toy and became fascinated by the fact that I could reflect light into dark places where the sun would never shine — in deep holes and crevices and dark closets. It became a game for me to get light into the most inaccessible places I could find.

I kept the little mirror, and as I went about my growing up, I would take it out in idle moments and continue the challenge of the game. As I became a man, I grew to understand that this was not just a child’s game but a metaphor for what I might do with my life. I came to understand that I am not the light or the source of light. But light — truth, understanding, knowledge — is there, and it will only shine in many dark places if I reflect it.

I am a fragment of a mirror whose whole design and shape I do not know. Nevertheless, with what I have I can reflect light into the dark places of this world — into the black places in the hearts of men — and change some things in some people. Perhaps others may see and do likewise. This is what I am about. This is the meaning of my life.”

And then he took his small mirror and, holding it carefully, caught the bright rays of daylight streaming through the window and reflected them onto my face and onto my hands folded on the desk.

Much of what I experienced in the way of information about Greek culture and history that summer is gone from memory. But in the wallet of my mind I carry a small round mirror still.

Are there any questions?

_________________________________

Related Libby’s H*O*P*E*™ Postings:

“Smile, Open Your Eyes, Love and Go On.,” by Paul Cacciatore, July 28, 2010.

Vox Populi*: Libby, We’ll Be Missing You, by Paul Cacciatore, July 28, 2009.

A Requiem Hallelujah, But Don’t Let There Be a Hole in the World Tomorrow, by Paul Cacciatore, July 28, 2008.

2011 ASCO: Additional Phase III Study Data Support the Potential Role of Avastin in Newly-Diagnosed & Recurrent Ovarian Cancer

Posted on June 9, 2011 by Paul Cacciatore

Positive results from two bevacizumab (Avastin®) phase III clinical studies were presented at the 2011 American Society of Clinical Oncology Annual Meeting on June 4. The data reported add to the growing body of evidence in support of bevacizumab use to treat recurrent and newly-diagnosed ovarian cancer.

Positive results from two bevacizumab (Avastin®) phase III clinical studies were presented at the 2011 American Society of Clinical Oncology Annual Meeting on June 4. The data reported add to the growing body of evidence in support of bevacizumab use to treat recurrent and newly-diagnosed ovarian cancer.

About Bevacizumab (Avastin®)

A diagram illustrating the role of the VEGF protein in the formation of new blood vessels that support tumor growth. Click on the picture above to view a video regarding the mechanism of action with respect to bevacizumab (Avastin®). (Photo: Genentech)

“Angiogenesis” refers to the process of new blood vessel formation. When tissues need more oxygen, they release molecules that encourage blood vessel growth. Angiogenesis is a normal and vital process in human growth and development, as well as in wound healing. Unfortunately, cancer tumors also utilize this same process to enhance their own blood supply in order to nourish their aberrant growth.

Ovarian cancer is associated with high concentrations of vascular endothelial growth factor (VEGF), a protein associated with tumor growth and spread. Studies have shown a correlation between a high concentration of VEGF and ascites (excess fluid in the body cavity) development, disease worsening, and a poorer prognosis in women with ovarian cancer.[1-2]

Bevacizumab is a humanized monoclonal antibody designed to specifically bind to the VEGF protein, which plays an important role throughout the lifecycle of the tumor to develop and maintain blood vessels through angiogenesis. The drug interferes with the tumor blood supply by directly binding to the VEGF protein to prevent interactions with receptors on blood vessel cells. The tumor blood supply is thought to be critical to a tumor’s ability to grow and spread in the body (metastasize).

Bevacizumab is the first U.S. Food and Drug Administration (FDA) approved therapy designed to inhibit angiogenesis. Although FDA-approved for several forms of cancer, bevacizumab is not yet approved for the treatment of ovarian cancer. Patients treated with bevacizumab may experience side effects. In past clinical trials, some people treated with bevacizumab experienced serious and sometimes fatal side effects, related to gastrointestinal (GI) perforation, surgery and wound healing, and severe bleeding. For more information, review the Avastin BOXED WARNINGS and Additional Important Safety Information.

OCEANS Phase III Clinical Study: Women with Recurrent Platinum Sensitive Ovarian Cancer Experience 78% Response Rate & 52% Reduction In Disease Progression Risk

About the OCEANS Study

“OCEANS” is a multicenter, randomized, double-blind, placebo-controlled Phase III study in 484 women with platinum drug-sensitive recurrent ovarian, primary peritoneal or fallopian tube cancer.[3] Women in the OCEANS study received no more than one treatment regimen prior to study enrollment. The OCEANS study randomized enrolled women to one of two clinical study arms:

Arm A: Intravenous carboplatin (area under the curve (AUC) 4; Day 1) + gemcitabine (1,000 mg/m2; Day 1 & 8; brand name: Gemzar®) + placebo (Day 1) every 21 days x 6 cycles, followed by placebo maintenance every 21 days, until disease progression or unacceptable toxicity occurred.

Arm B: Carboplatin + gemcitabine + bevacizumab (15 mg/kg; Day 1) every 21 days x 6 cycles, followed by single agent bevacizumab maintenance every 21 days, until disease progression or unacceptable toxicity occurred.

The primary endpoint of the OCEANS study was progression free survival. The secondary endpoints of the study included overall survival, objective response, duration of response and safety profile.

OCEANS Study Data

Carol Aghajanian, M.D. speaks during the Oral Abstract Session: Gynecologic Cancer at the American Society of Clinical Oncology Annual Meeting on Saturday June 4, 2011. (Photo: ASCO/GMG/Silas Crews 2011)

Carol Aghajanian, M.D., chief of the gynecologic medical oncology service at Memorial Sloan-Kettering Cancer Center, presented the data from the OCEANS study comparing efficacy and safety of chemotherapy and antiangiogenic therapy in platinum drug-sensitive recurrent ovarian cancer.

Two hundred forty-two women were allocated to each study arm and the median follow-up period was 24 months. Patient characteristics were well-matched in the two treatment groups with regard to age (median age ~60), race (~91% white), performance status (~75%, PS = 0), histologic subtype (~80% serous), cytoreductive surgery (~11%), and platinum-free interval (defined as the time between finishing front-line platinum-based therapy and starting second-line chemotherapy) of more than 12 months (~60%). The study stratification variables were platinum-free interval (6 to 12 months vs. more than 12) and cytoreductive surgery for recurrent disease (yes vs. no).

The median number of chemotherapy cycles was six for each group, and a median of 11 cycles of bevacizumab or placebo was given. At least one-third of the patients received more than six cycles of carboplatin and gemcitabine, although slightly more of the placebo-treated group continued chemotherapy beyond six cycles.

Progression-free survival was significantly longer for women given bevacizumab (12.4 months vs. 8.4 months in the placebo-treated group (hazard ratio [HR]: 0.484; 95% confidence interval (CI) [0.388, 0.605]; p < 0.0001). These results were corroborated by the analyses of an independent review committee. Analyses according to platinum-free interval, cytoreductive surgery, age, and baseline performance status indicate a consistent benefit in all subgroups.

Objective response rate increased by 21.1% (p < 0.0001), from 57.4% in the placebo group to 78.5% in the bevacizumab treated group; duration of response increased from a median of 7.4 months to 10.4 months, respectively (HR: 0.534; 95% CI [0.408, 0.698]; p < 0.0001). Overall survival data are still premature, with median survival of 29.9 months in the placebo group and 35.5 months in the bevacizumab treatment group.

Sixty-five percent of the patients in the placebo group were withdrawn from the protocol due to disease progression, compared with only 41% of the treatment group, but 23% of the discontinuations in the bevacizumab group were due to adverse events, compared with only 5% in the placebo group. Much of this increase was due to grade 3 (or worse) adverse events; specifically hypertension and proteinuria associated with bevacizumab therapy. Overall, the safety profile of bevacizumab was consistent with past trials.

OCEANS Study Commentary

Dr. Aghajanian concluded that the OCEANS study results demonstrate a statistically significant and clinically relevant benefit when bevacizumab is added to carboplatin and gemcitabine. Aghajanian stated that this regimen should be considered a new option for the treatment of recurrent, platinum drug-sensitive ovarian cancer. As expected, the rate of adverse events was higher among patients who received bevacizumab, explained Dr. Aghajanian. “Hypertension and proteinuria were increased, but febrile neutropenia was the same in both arms.” “The safety data are reassuring and consistent with the known bevacizumab side-effect profile, and there were no new safety signals,” said Dr. Aghajanian.

“In advanced ovarian cancer, just as in advanced breast cancer, there is often an opportunity to intervene with different lines of chemotherapy,” said Andrew Seidman, M.D., attending physician for the breast cancer medicine service at Memorial Sloan-Kettering Cancer Center and professor of medicine at Weill Medical College of Cornell University. “There are many chapters in the story, so to speak,” said Dr. Seidman, who moderated a press briefing held in advance of the presentation. “We want to prolong each and every chapter in the disease, and make the story longer and ultimately improve survival. These trials results are certainly an important step in that direction.”

“Women with recurrent ovarian cancer need new treatment options, and it is therefore an important advance to halve the risk of disease progression in this incurable cancer,” said Hal Barron, M.D., chief medical officer and head of Roche Holdings Global Product Development. “These data add to the growing body of evidence supporting Avastin’s potential role in this disease, which includes two previously presented Phase III clinical trials [Gynecologic Oncology Group (GOG)-218 [4] & ICON7] in women with newly diagnosed ovarian cancer.”

In his discussion of the study, Anil K. Sood, M.D., professor and director of the Blanton-Davis Ovarian Cancer Research Program in the Departments of Gynecologic Oncology and Cancer Biology at the University of Texas M.D. Anderson Cancer Center, suggested that further understanding of the timing and dosing of bevacizumab should be pursued in light of (i) its great financial cost, and (ii) reports that inhibition of angiogenesis in animal models reduces primary cancer tumor growth, but accelerates invasion and metastasis — unintended consequences that might be linked to the failure of bevacizumab to extend overall survival in most clinical trials.

ICON7 Phase III Clinical Study: Newly-Diagnosed Women with High-Risk Ovarian Cancer Experience 36% Reduction in Risk of Death

Gunnar Kristensen M.D., Ph.D. speaks during the Women's Cancers Press Briefing at the American Society of Clinical Oncology Annual Meeting on June 4, 2011. (Photo: ASCO/GMG/Scott Morgan 2011)

ICON7 was designed to investigate safety and efficacy of adding bevacizumab to standard chemotherapy in women with newly diagnosed ovarian cancer. [5] Gunnar Kristensen, M.D, Ph.D., senior consultant in the Department for Gynecologic Oncology of the Norwegian Radium Hospital located in Oslo, reported the Phase III clinical study results.

About the ICON7 Study

From December 2006 to February 2009, 1,528 women were randomized from 263 centers in 7 Gynecologic Cancer InterGroups. Eligible women with high-risk early FIGO (Federation of International Gynecology and Obstetrics) stage I or IIa (grade 3 or clear cell histology), capped ≤10%) or advanced (stage IIb-IV) epithelial ovarian, primary peritoneal or fallopian tube cancer were randomizsed (1:1) to one of two study arms:

Arm A: 6 cycles of 3 weekly chemotherapy (carboplatin AUC 5 or 6 and paclitaxel 175mg/m2) alone; or

Arm B: Same chemotherapy as in Arm A, given concurrently with bevacizumab (7.5mg/kg) for 5 or 6 cycles, followed by continued 3-weekly single-agent bevacizumab maintenance therapy for 12 additional cycles (up to 12 months) or until disease progression (whichever event occurs first).

The baseline patient characteristics were balanced between both study arms: median age (57 years); ECOG Performance Status 0-1 (47%); high-risk early-stage disease (9%); poor prognosis patients (30%); histology (69% serous, 8% endometrioid, 8% clear cell).

Updated ICON7 Progression Free Survival Data

Data from the ICON7 study were presented for the first time at the 2010 European Society of Medical Oncology (ESMO) Congress. As reported at ESMO, chemotherapy-naïve ovarian cancer patients who received bevacizumab in combination with standard chemotherapy, and then continued with single agent bevacizumab maintenance therapy, experienced approximately 27% improvement (18.3 months versus 16 months) in the likelihood of living longer without the disease worsening (i.e., progression-free survival) compared to those women who received only chemotherapy (hazard ratio = 0.79, p=<0.0010), which corresponds to a 21% reduction in risk of cancer progression or death. The ICON7 data presented at ESMO was based upon mature progression-free survival results.

The updated ICON7 progression-free survival data presented at the ASCO annual meeting were consistent with the data reported last year at ESMO. In the updated analysis, women assigned to the bevacizumab arm experienced longer progression-free survival than those in the control group (19.8 months vs 17.4 months; HR, 0.87; p =.039). “There is a substantial prolongation of time to progression,” said Dr. Kristensen, adding that the gain was 2.4 months.

ICON7 Overall Survival Data Immature; But Clear Benefit To Women With “Poor Prognosis.”

At a median follow-up of 28 months, there were fewer deaths among women who received bevacizumab than among those who received standard chemotherapy (178 vs 200). Although this represents a 15% overall reduction in mortality risk, the difference did not reach statistical significance (hazard ratio [HR], 0.85; P = .11). The final analyses for overall survival will be performed when 715 patient deaths have occurred. The current analysis was conducted because an interim analysis with at least 365 deaths was requested by the FDA and the European Medicines Agency for licensing consideration.

Although the overall survival data is not mature, a subgroup analysis of women with a “poor prognosis” (defined as FIGO stage III patients debulked to >1.0cm of visible diease or FIGO stage IV with debulking) was performed. Within this subgroup, there were 79 deaths within the bevacizumab arm and 109 deaths in the control arm. Based on this data, there was a 36% reduction in the risk of death (HR=0.64, 95% CI=0.48 to 0.85, p=0.0022 with p=0.015 for test for interaction (treatment/risk group)) among the poor prognosis subgroup. This result was statistically significant. “We have previously shown that [the high-risk] group has a greater benefit from bevacizumab than the other patients,” said Dr. Kristensen. “For this group, there is a very clear gain for overall survival.”

ICON7 Study Commentary

“We conclude that the addition of concurrent and continued bevacizumab for 12 months does improve progression-free survival,” said Dr. Kristensen. Kristensen also noted that, on the basis of an interim analysis involving approximately 53% of the number of deaths needed for the final analysis, there is an overall trend for improvement in overall survival.

“In this study, we see the ability of antiangiogenic therapy to delay the progression of ovarian cancer, this time in the first-line setting,” said Andrew Seidman, M.D. He added that previous studies have demonstrated the efficacy of bevacizumab in ovarian cancer. “These lend support to a potential role for bevacizumab as the first biologic agent to be used in this disease,” said Seidman, who moderated a press briefing during which study highlights were presented.

There are many strengths in a study like this, in that it addresses questions about the role of anti-VEGF therapies in this setting, said Anil Sood, M.D., who served as a discussant for this paper. “The randomized design is obviously a major strength.”

However, there are potential issues to examine, explained Dr. Sood. “One is the role of bevacizumab in the combination setting, compared with the maintenance setting.”

“How useful is bevacizumab in the combination setting up front? Is the real role for bevacizumab in the maintenance setting following initial chemotherapy,” he asked.

The issue of bevacizumab dosing was also raised by Dr. Sood. “One of the questions is whether higher doses are needed,” he said. “There are data emerging from other studies showing that lower doses are as efficacious, if not more so.”

References:

1/Rudlowski C, Pickart AK, Fuhljahn C, et. al. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:183-9. PubMed PMID: 16515588.

2/Cooper BC, Ritchie JM, Broghammer CL, et. al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res. 2002 Oct;8(10):3193-7. PMID: 12374688

3/Aghajanian C, Finkler NJ, Rutherford T, et. al. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 29: 2011 (suppl; abstr LBA5007)[2011 American Society of Clinical Oncology Annual Meeting].

4/ Burger RA, Brady MF, Bookman MA, et. al. Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study [GOG 218 Abstract]. J Clin Oncol 28:18s, 2010 (suppl; abstr LBA1).

5/Kristensen G, Perren T, Qian W., et. al. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J Clin Oncol 29: 2011 (suppl; abstr LBA5006) [2011 American Society of Clinical Oncology Annual Meeting].

Additional Sources & Helpful Information:

Bevacizumab Benefits Patients With Recurrent Ovarian Cancer, by Roxanne Nelson; American Society of Clinical Oncology (ASCO®) 2011 Annual Meeting, Medscape Today Medical News, June 5, 2011.

Bevacizumab Plus Chemo Improves Survival in Ovarian Cancer, by Roxanne Nelson; American Society of Clinical Oncology (ASCO®) 2011 Annual Meeting, Medscape Today Medical News, June 5, 2011.

Bevacizumab Prolongs Progression-free Survival for Women with Platinum-sensitive Recurrent Ovarian Cancer, American Society of Clinical Oncology (ASCO®) 2011 Annual Meeting, ASCO Daily News (Section 6A), June 6, 2011.

Incorporating Bevacizumab into Ovarian Cancer Treatment: Practical Considerations, by By Alexandra Leary, M.D., and Martin Gore, Ph.D., FRCP, Gynecologic Oncology Category, Educational Book, 2011 American Society of Clinical Oncology Annual Meeting, June 3-7, 2011. [Full Text Adobe Reader PDF document]

Bevacizumab (Avastin®) Clinical Trial Information

A list of open ovarian cancer clinical trials involving bevacizumab.

A list of open solid tumor clinical trials involving bevacizumab.

ICON7 – A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer (NCT00483782), Clinical Trial Protocol Summary, ClinicalTrials.gov.

A Phase III, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma (OCEANS) (NCT00434642), Clinical Trial Protocol Summary, ClinicalTrials.gov.

Related WORD of HOPE Ovarian Cancer Podcast™

10 Exciting Ovarian Cancer Research Topics from 2010 — Avastin Phase III Clinical Trials (Topic #1 of 10); Episode #1; WORD of HOPE Ovarian Cancer Podcast™, March 25, 2011.

Related Libby’s H*O*P*E*™ Postings

2011 NCCN Conference: New Treatment Options Lead to Steady Progress Against Ovarian Cancer, March 15, 2011.

Ohio State University Reports That Ovarian Cancer Drug Bevacizumab Is Not Cost-Effective, March 8, 2011.

Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer, February 25, 2010.

Related Libby’s H*O*P*E*™ Videos

To view videos regarding bevacizumab (Avastin®), click here.

Libby’s HOPE & Women’s Oncology Research & Dialogue Launch New “WORD of HOPE™” Ovarian Cancer Educational Podcast Series

Posted on May 13, 2011 by Paul Cacciatore

WORD OF HOPE™ Ovarian Cancer Podcast Now Available Through New Website, iTunes, YouTube, and Other Online Sources.

A new ovarian cancer educational podcast series, entitled “WORD of HOPE™,” was launched during Women’s Health Awareness Week through a collaborative initiative of Libby’s H*O*P*E*™ (LH) and Women’s Oncology Research & Dialogue (WORD).

The WORD of HOPE™ Ovarian Cancer podcast series will address important topics related to ovarian cancer, including prevention, early detection, diagnosis, groundbreaking treatments, scientific and clinical research information, and related women’s health information for ovarian cancer patients, caregivers and advocates. The WORD of HOPE™ podcast series can be found online at http://www.wordofhopepodcast.com, and is available to viewers and listeners for subscription at the WORD Of HOPE™ podcast website, iTunes, and YouTube.

“From the beginning, WORD has been committed to taking the most important scientific information and providing patients, caregivers and advocates the easily accessible resources to educate and inspire during their journey of care. As a physician, nearly every day we are looking for resources to give newly diagnosed patients and their supporters to help them better understand their diagnosis and treatment options. We are proud to partner with Libby’s H*O*P*E*™ and its founder Paul Cacciatore in the production of these new podcasts,” said Dr. John Geisler, WORD co-founder and Director of Gynecologic Oncology at University of Toledo.

Paul Cacciatore, Libby’s H*O*P*E* founder and podcast co-host said: “The WORD of HOPE™ ovarian cancer podcast series embodies the age old adage that ‘information is power’ — a potentially life-saving concept in the fight against the most lethal gynecologic cancer.” Mr. Cacciatore emphasized that the information featured in the podcast series is easy to understand and accessible from anywhere, including at home, on the job, or on the go through a smartphone or iPad. “WORD of HOPE™ not only raises much-needed ovarian cancer awareness in the minds of the general public, it educates survivors to proactively participate in their treatment through more meaningful dialogue with their doctors. Libby’s H*O*P*E* is proud to partner with WORD through this global form of social media.”

The first podcast installment will feature the following seven episodes (three already posted; four pending) which address ten significant 2010 scientific research and clinical treatment topics within the field of ovarian cancer:

Avastin (Bevacizumab) Phase III Clinical Trials;
PARP Inhibitors & BRCA Gene-Mutated Ovarian Cancer;
NKTR-102, AMG 386, “Dose Dense” Paclitaxel (Taxol), and the Carboplatin/Pegylated Liposomal Doxorubicin (Doxil®) Drug Combination;
ARID1A Gene Mutation In Endometriosis-Associated Ovarian Cancers;
Reliance Upon CA-125 To Determine Ovarian Cancer Recurrence;
Neoadjuvant Chemotherapy For Advanced Ovarian Cancer; and
Diagnosis of Early Stage Ovarian Cancer: Risk of Ovarian Cancer Algorithm (ROCA) & Human Epididymis Protein 4 (HE4).

Viewers or listeners of WORD of HOPE™ Ovarian Cancer Podcast can contact Nathan Manahan, WORD Executive Director, via email to provide feedback and ideas for the podcast. To listen, watch or subscribe to the podcast series, visit http://www.wordofhopepodcast.com.

About the WORD of HOPE™ Podcast

Based in Indianapolis, Indiana (WORD) and Los Angeles, California (LH), WORD of HOPE™ serves viewers and listeners interested in up-to-date ovarian cancer information. Hosted by Nathan Manahan and Paul Cacciatore, WORD of HOPE™ ovarian cancer podcasts will be released several times a month and available for subscription through iTunes, RSS and YouTube.

About Women’s Oncology Research & Dialogue

Co-founded by gynecologic oncologists Drs. Kelly Manahan and John Geisler, WORD is an Indianapolis-based nonprofit organization dedicated to helping women conquer gynecologic cancers through catalyzing innovative scientific and clinical research, which results in empowering educational resources for women’s organizations and medical personnel regarding proper prevention, diagnosis and treatment.

About Libby’s H*O*P*E*™

Paul Cacciatore established Libby’s H*O*P*E*(*Helping *Ovarian Cancer Survivors *Persevere Through *Education)™ in March 2008 as an online resource to assist his 26-year-old cousin, Elizabeth “Libby” Remick, who was battling advanced-stage ovarian cancer. Although Libby ultimately lost her battle to the disease, Paul continues to assist ovarian cancer survivors worldwide, and their families and friends, through the website under the principle that “information is power” in the fight against ovarian cancer. Through Libby’s H*O*P*E*™, Paul has published approximately 250 weblog articles relating to ovarian cancer and cancer-related topics. Libby’s H*O*P*E*™ utilizes a variety of online media resources and social networks to disseminate critical information relating to ovarian cancer awareness, including the early warning signs and symptoms of the disease, important medical discoveries, relevant current clinical trials, and most importantly, stories of hope involving ovarian cancer survivors and their families. To learn more, visit https://healthinfoispower.wordpress.com

For more information, contact Executive Producer, Chad Braham at 317-855-8144 or visit the official website: http://www.wordofhopepodcast.com.

Libby’s HOPE™ National Ovarian Cancer Coalition 6th Annual Women’s Health Expo Presentation

Posted on April 2, 2010 by Paul Cacciatore

On March 20, 2010, Libby’s H*O*P*E*™ made a presentation at the National Ovarian Cancer Coalition’s 6th Annual Women’s Health Expo. The presentation was entitled, A Patient Advocate’s Perspective on the Importance of Ovarian Cancer Awareness and Helpful Online Resources.

On March 20, 2010, Libby’s H*O*P*E*™ made a presentation at the National Ovarian Cancer Coalition’s 6th Annual Women’s Health Expo. The presentation was entitled, A Patient Advocate’s Perspective on the Importance of Ovarian Cancer Awareness and Helpful Online Resources. The topics covered in the presentation include:

Genesis of Libby’s H*O*P*E*™,
Ovarian Cancer Overview,
Helpful Online Resources,
Stories of Hope, and
Making a Difference

The full presentation is provided below in Adobe Reader PDF document format. To view the full presentation, simply click on the image below. If you require free Adobe Reader software, click here.

I want to extend special thanks to Nancy Long and Paula Kozik, co-presidents of the National Ovarian Cancer Coalition’s Central Maryland Chapter, for the invitation to speak at this worthwhile event. Nancy and Paula are two very special ovarian cancer survivors, who put together an informative conference that was well attended and enjoyed by all. It was both an honor and a privilege to meet Nancy, Paula, and many other ovarian cancer survivors during the conference. Many women shared with me their personal stories of struggle, inspiration and hope. These women are my “everyday heroes.” If you have any questions regarding the presentation, please feel free to contact me by clicking on the homepage “Contact” tab.

Libby’s HOPE to Present At NOCC 6th Annual Women’s Health Expo (REJUVENATE Finding Balance)

Posted on February 15, 2010 by Paul Cacciatore

On March 20, 2010, the National Ovarian Cancer Coalition (Maryland Chapter) will hold its 6th Annual Women’s Health Expo entitled, REJUVENATE Finding Balance (NOCC Rejuvenate), at the Sheraton Annapolis Hotel. … On behalf of Libby’s H*O*P*E*™, I will conduct a seminar as part of Session II entitled, A Patient Advocate’s Perspective on the Importance of Ovarian Cancer Awareness and Related On-line Resources.

On March 20, 2010, the National Ovarian Cancer Coalition (Maryland Chapter) will hold its 6th Annual Women’s Health Expo entitled, REJUVENATE Finding Balance (NOCC Rejuvenate), at the Sheraton Annapolis Hotel. NOCC Rejuvenate is sponsored by the National Breast & Ovarian Cancer Connection and Cancer Treatment Centers of America. Additional funding was also provided through a grant from the Maryland Attorney General Settlement.

NOCC Rejuvenate is designed to appeal to all women who want to rejuvenate their mind, body and spirit. The event is divided into three sessions. Each session offers seven to eight different seminars for attendees. The seminars address a variety of topics including make-up and skin care, going green, photography, plastic surgery, decorating, fashion, finance, retirement solutions, nutrition, fitness, and holistic approaches to wellness. A list of all event seminars is provided below.

Informative seminars about ovarian and breast cancer are offered as part of each session. Knowing the signs and symptoms of ovarian cancer, the screening guidelines for breast cancer, and the basics about hereditary breast and ovarian cancer, could save your life or the life of someone you love. On behalf of Libby’s H*O*P*E*™, I will conduct a seminar as part of Session II entitled, A Patient Advocate’s Perspective on the Importance of Ovarian Cancer Awareness and Related On-line Resources. My presentation will address the genesis of the Libby’s H*O*P*E*™ website; highlight critical ovarian cancer awareness information; summarize available online ovarian cancer and cancer-related resources; describe stories of hope involving ovarian cancer survivors and their families; and explain how each individual can make a difference in the fight against ovarian cancer.

NOCC Rejuvenate also targets cancer survivors. The devastating effects of these diseases can rob women of hope and peace. This event will offer an opportunity for survivors to reinvent their self-image and gain more knowledge, offering a sense of hope and a chance to connect with other survivors.

An exhibitor’s area will be offered at the event. This area will include informational tables as well as vendor tables that have been specifically chosen to meet the overarching vision of the event. At the completion of the three event sessions, a nutritious lunch will be served while information is provided on the signs and symptoms of ovarian and breast cancer.

NOCC 6th Annual Women's Health Expo

What: National Ovarian Cancer Coalition 6th Annual Women’s Health Expo entitled, REJUVENTE Finding Balance (click here to view event brochure, including mail-in registration)

When: Saturday, March 20, 2010 (8:00 A.M. – 3:00 P.M.)

Where: Sheraton Annapolis Hotel, 173 Jennifer Road, Annapolis, Maryland 21401 (driving instructions).

Register: To register online click here.

Contact: Nancy Long (NOCC Maryland Chapter Co-President) at 443-433-2597, or email (click here).

Keynote Speaker: Yarrow, The Energy Whisperer

Session I Presentations (9:30 A.M. – 10:30 A.M.)

Treating Cancer By Alternative Medicine

The Survivors’ Connection

The Skinny on Fat – Cancer Prevention Naturally

Interior Design in Difficult Times – Cost Saving Design Solutions

Relaxation & Healing

Identifying & Solving the Challenges of Baby Boomer Women

Cancer and The Healing Power of Forgiveness

Belly Dancing

Session II Presentations (10:45-11:45)

Dr. Zandra Cheng, Breast Surgeon at Anne Arundel Medical Center

Hereditary Syndromes That Include Ovarian and Breast Cancers

Facial & Body Rejuvenation

A Patient Advocate’s Perspective On the Importance of Ovarian Cancer Awareness & Related On-line Resources (Paul Cacciatore, Founder, Libby’s H*O*P*E*™)

Designing Green Interiors

Creating Better Images with the Camera You Own

Some Expert Fashion Tips

Yoga: A Balanced Life

Relaxation & Healing

Session III Presentations (12:00 P.M. – 1:00 P.M.)

New Advances in Ovarian Cancer (William McGuire, M.D., Medical Director of The Harry & Jeanette Weinberg Cancer Institute at Franklin Square Hospital)

What is My Daughter’s Chance of Getting My Cancer?

Planning for your Retirement Lifestyle: The New Retirement

Super Health Begins with Super-food Nutrition

Around the World to Your Backyard

Balancing Your Life Wheel

Get Fit & Healthy with the Simple Rules of the Big 3

Relaxation & Healing

About the National Ovarian Cancer Coalition

The mission of the NOCC is to raise awareness and increase education about ovarian cancer. NOCC is committed to improving the survival rate and quality of life for women with ovarian cancer. Through national programs and local Chapter initiatives, the NOCC’s goal is to make more people aware of the early symptoms of ovarian cancer. In addition, the NOCC provides information to assist the newly diagnosed patient, to provide hope to survivors, and to support caregivers. NOCC programs are possible only with the help of its volunteers; committed men and women dedicated to the mission of the NOCC in communities across the country. For more information go to http://www.ovarian.org/.

About the National Breast & Ovarian Cancer Connection

The mission of the NBOCC is to raise awareness and educate the general public about the link between breast and ovarian cancer. The organization is dedicated to teaching all women about their inherent risks and how to improve their chances of survival through early detection and research developments. For more information go to http://www.nbocc.org/.

Meet Laurey Masterton, 20-Year Ovarian Cancer Survivor Extraordinaire

Posted on March 20, 2009 by Paul Cacciatore

To call Laurey Masterton an “overachiever” is akin to calling Lance Armstrong a “decent” bike rider. …On March 6, 2009, Laurey dipped her rear bicycle tire into the Pacific Ocean (San Diego, CA), and started a 58-day, 3100-mile trek that will culminate in the dipping of her front bicycle tire into the Atlantic Ocean (St. Augustine, FL) on or about April 30th. … The purpose of her bike trip is to raise awareness about ovarian cancer. …

To call Laurey Masterton an “overachiever” is akin to calling Lance Armstrong a “decent” bike rider. A few of Laurey’s amazing talents and achievements (past & present) include the following:

Laurey Masterton, 20-Year Ovarian Cancer Survivor, Bikes Across America to Raise Awareness About the Early Warning Signs & Symptoms of Ovarian Cancer (Photo Source: Ovarian Cancer National Alliance)

Graduate from the University of New Hampshire;
Outward Bound Instructor who co-created and instructed the first Outward Bound courses for cancer survivors at The North Carolina Outward Bound School;
Intern for Nora Pouillion, the creator of the first 100 percent certified organic restaurant in the U.S.;
Founder of Laurey’s Catering & Gourmet to Go, a very successful catering business and shop for “gourmet comfort food;”
Author of Elsie’s Biscuits:Simple Stories of Me, My Mother, and Food, a “culinary memoir-with recipes” in which she tells about growing up in the golden light of a small inn, losing her parents as a child, and then finding her way back to them through food and stories;
In 1999, Laurey was awarded the Small Business Leader of the Year for both Asheville, North Carolina and the state of North Carolina;
In 2001, Laurey was the recipient of The Athena Award, which promotes women’s leadership and honors outstanding leaders;
Board Chair of the Asheville Area Chamber of Commerce;
Board Member of the Appalachian Sustainable Agriculture Project;
Participant in local farm-to-table initiatives, with a particular interest in helping children experience gardening, cooking and the eating of “real food;”
Glassblowing student, who collects sea urchins, antique chafing dishes, and old Clementine boxes;
Italian speaking leader of guided culinary tours to the Tuscany region of Italy and the Provence region of France;
Active long-distance bike rider and beekeeper;
Resident of Asheville, North Carolina, where she lives with her partner Chris and her dog Tye;
Follower of the motto “don’t postpone joy;” and
20-year survivor of ovarian cancer, one of the deadliest cancers affecting women today.

Yup, I “buried the lead” as they say in journalism. Laurey is a 20-year ovarian cancer survivor who fully recognizes and appreciates her good fortune. As you probably guessed by now, the appreciation of good fortune is simply not enough for Laurey. On March 6, 2009, Laurey dipped her rear bicycle tire into the Pacific Ocean (San Diego, CA), and started a 58-day, 3100-mile trek that will culminate in the dipping of her front bicycle tire into the Atlantic Ocean (St. Augustine, FL) on or about April 30th. The purpose of her bike trip is to raise awareness about the warning signs and symptoms of ovarian cancer and the dire need for early detection. In an interview with the Ovarian Cancer National Alliance (OCNA), Laurey said, “Being a 20-year ovarian cancer survivor is a special victory because sadly most of its victims don’t reach this milestone. I’m one of the lucky ones because I was able to feel symptoms early on and was diagnosed in Stage I. I was in touch with my body, I knew something was wrong, I was persistent with the doctors and it saved my life. Early detection and awareness of ovarian cancer is the message that I want my bike ride to convey.”

Historically ovarian cancer was called the “silent killer” because symptoms were not thought to develop until the chance of cure was poor. However, recent studies have shown this term is untrue and that the following symptoms are much more likely to occur in women with ovarian cancer than women in the general population. These symptoms include:

Bloating

Pelvic or abdominal pain

Difficulty eating or feeling full quickly

Urinary symptoms (urgency or frequency)

As in Laurey’s case, women with ovarian cancer report that symptoms are persistent and represent a change from normal for their bodies. The frequency and/or number of such symptoms are key factors in the diagnosis of ovarian cancer. Several studies show that early stage ovarian cancer can produce these symptoms. Women who have these symptoms daily for more than a few weeks should see their doctor, preferably a gynecologist. Prompt medical evaluation can lead to detection at the earliest possible stage of the disease which is associated with an improved prognosis. Additional symptoms can include fatigue, indigestion, back pain, pain with intercourse, constipation and menstrual irregularities.

The ovarian cancer facts and figures published by the American Cancer Society in 2008 note the following:

Ovarian cancer can afflict adolescent, young adult, and mature women, although the risk of disease increases with age and peaks in the late 70s. Pregnancy and the long-term use of oral contraceptives reduce the risk of developing ovarian cancer.

There is no reliable screening test for the detection of early stage ovarian cancer. Pelvic examination only occasionally detects ovarian cancer, generally when the disease is advanced. However, the combination of a thorough pelvic exam, transvaginal ultrasound, and a blood test for the tumor marker CA125 can be offered to women who are at high risk of ovarian cancer and to women who have persistent, unexplained symptoms like those listed above.

If diagnosed at the localized stage, the 5-year ovarian cancer survival rate is 92%; however, only about 19% of all cases are detected at this stage, usually fortuitously during another medical procedure.

For women with regional and distant metastatic disease, the 5-year ovarian cancer survival rates are 71% and 30%, respectively. The 10-year relative survival rate for all stages combined is 38%.

Women who have had breast cancer, or who have a family history of breast cancer or ovarian cancer may have increased risk. Inherited mutations in BRCA1 or BRCA2 genes increase risk. Women of Ashkenazi (European) Jewish ancestry are at greater risk for inherited BRCA gene mutations. Another genetic syndrome, hereditary nonpolyposis colon cancer (also known as “Lynch syndrome”), has also been associated with endometrial and ovarian cancer.

Ovarian cancer incidence rates are highest in Western industrialized countries.

Ovarian cancer accounts for about 3% of all cancers among women and ranks #2 among gynecologic cancers.

An estimated 21,650 new ovarian cancer cases were diagnosed in the U.S.

An estimated 15,520 ovarian cancer deaths occurred.

Ovarian cancer causes more deaths than any other cancer of the female reproductive system.

Prior to starting her trip, Laurey Masterton raised a portion of her $50,000 goal amount that will be donated to (i) OCNA, in support of its work on research, education, and awareness essential to the fight against ovarian cancer, and (ii) the Women Chefs and Restaurateurs (WCR), an organization that promotes and enhances the education, advancement and connection of women in the culinary industry. In turn, the OCNA and WCR are partnering with Laurey in her efforts to raise ovarian cancer awareness. “Laurey is an inspiration to women everywhere to never give up and always to have hope no matter how big the obstacle,” says Karen Orloff Kaplan, CEO of OCNA. “We are delighted to support Laurey throughout her bike ride and help her reach her goals in bringing more attention to ovarian cancer.”

Laurey is journaling online in “real time” about various aspects of her ongoing bike trip at www.laureybikes.blogspot.com. On Saturday, March 14th, Laurey stopped at Apache Junction, Arizona to chat with several ovarian cancer survivors. In one of Laurey’s most touching journal entries to date, entitled A morning to chat, Laurey writes:

(Photo Source: Laurey Bikes at http://www.laureybikes.blogspot.com)

* * *

These sweet lovelies came to see me off this morning. FIRST thing! Ovarian cancer survivors (the woman on my left is a 38 year survivor!) and supporters, they arrived, armed with teal feather boas and a video camera and good questions. The sun rose over those fragrant eucalyptus trees and we talked about riding and surviving and persisting in the face of chemotherapy or miles and miles of uphill, bumpy roads.

Before I left Asheville I had a Reiki session with a friend and told her that I was not sure I was doing the right thing by leaving my business and my home and my friends and my life to go gallivanting around on my red Trek. She said I would find signs to tell me I WAS doing the right thing. She said, “Your spirit guides will tell you. They especially like to show themselves in the form of pennies and feathers.”

Ha!

Here they are.

* * *

I encourage everyone to check out Laurey’s Google Map below, which sets forth her anticipated travel route and stops. As of this writing, Laurey was leaving Lordsburg, New Mexico, so please visit Laurey’s blog to learn how you can support her during her cross-country bike ride.

If I were a betting man, I would say that there is no doubt that Laurey will complete her cross country trek, while educating thousands of women about the warning signs and symptoms of ovarian cancer, and the need for early detection. Throughout her entire life, Laurey did not allow difficult life circumstances and past achievements to define her. Nothing has changed. She always moves forward, living by the motto “don’t postpone joy.” Laurey not only represents a strong role model for ovarian cancer survivors, she is an inspiring and passionate role model for anyone with a heartbeat.

Babe Ruth, the legendary baseball player, once said, “It’s hard to beat a person who refuses to give up.” A word to the wise: Never bet against Laurey because the word “quit” is not in her vocabulary!

In the video below, TV Personality and Chef Sara Moulton conducts an intimate interview with Laurey Masterton regarding her cross country bike ride to raise awareness about the early warnings signs and symptoms of ovarian cancer.

TV Personality & Chef Sara Moulton Interviews Laurey Masterton

About the Ovarian Cancer National Alliance

The Ovarian Cancer National Alliance (OCNA) is the nation’s vision and voice for ovarian cancer issues. The OCNA, a 501(c)(3) nonprofit organization, leads the national initiative to conquer ovarian cancer by uniting individuals and local, state and national organizations in a consolidated movement to advance ovarian cancer research, improve health care practice and find an effective screening test and a cure for the disease. To learn more about the OCNA, visit its website at www.ovariancancer.org.

About the Women Chefs and Restaurateurs

The mission of Women Chefs & Restaurateurs is to promote and enhance the education, advancement and connection of women in the culinary industry. Formed in 1993 by eight of the nation’s top women chefs and restaurateurs, WCR has grown to a membership of over 2,000 members, offering a variety of networking, professional and support services. To learn about WCR, visit its website at www.womenchefs.org.
____________________________________

Primary Source: 20-Year Ovarian Cancer Survivor Celebrates Golden Birthday – Chef Laurey Masterton Bikes 3,098 Miles Across US to Raise Awareness About Ovarian Cancer, Press Release, Ovarian Cancer National Alliance, March 4, 2009. Libby’s H*O*P*E*™ would like to extend a special thank you to Laurey Masterton and the Ovarian Cancer National Alliance for allowing us to feature Laurey’s story along with her photographs and google map.

Do You Twitter? Tell Libby’s HOPE What You’re Doing!

Posted on March 2, 2009 by Paul Cacciatore

Libby’s H*O*P*E*™ recently added a feed from its Twitter account (http://www.twitter.com/libbyshope) to the homepage left sidebar. I know what you are thinking. What in the heck is Twitter?

Twitter is a social networking service that allows its users to send and read other users’ updates (known as “tweets”), which are text-based messages that cannot exceed 140 characters. Updates are displayed on the user’s profile page and delivered to other users who have signed up to receive them. Senders can restrict delivery to those in their circle of friends (delivery to everyone being the default). In addition, users can receive message updates via the Twitter website, mobile phone, Blackberry, etc. It’s easy! Set up a Twitter account and choose to follow “libbyshope.” At this point, you will receive all Libby’s H*O*P*E*™ weblog updates no matter where you are located. You can perform a general search on the Twitter website for any topic (e.g., “cancer”) and you will find organizations and individuals who share your interest in that topic.

Twitter also allows you to send messages of 140 characters or less to Libby’s H*O*P*E*™. In those messages, you can add web links to relevant news or medical articles and even include pictures. If you attend a cancer conference, local hometown educational seminar or a fundraising event, you can send us brief comments (and pictures) directly from those events in real time. Or, if you just feel like telling us how you are doing, that’s ok too! Twitter allows cancer survivors to stay in touch with one through the communication of valuable information and advice.

Currently, we are streaming Libby’s H*O*P*E*™ outbound twitter messages to our weblog (left homepage sidebar), but if the interest is high enough, we will stream all messages received and sent by Libby’s H*O*P*E*™ on the weblog. By way of example, Libby’s H*O*P*E*™ is currently following the American Cancer Society, Association of Cancer Online Resources (ACOR), Cure Magazine, Lance Armstrong and several other cancer survivors and advocates.

The addition of Twitter to the Libby’s H*O*P*E*™ weblog is simply our way of allowing you to easily follow us regardless of your location. More importantly, we hope to hear from many of you through this technology in the near future. We provide below a video that describes “Twitter in plain English” and several additional links that will allow you to better understand Twitter.

Twitter in Plain English

Additional Resources:

Help Resources/Getting Started, Twitter.com.

Applications, Twitter.com. (we use twhirl as a desktop widget).

Tiny URL.com (application allows you to shorten any web address for inclusion in a Twitter message, thereby allowing you to minimize usage of the 140 character twitter message limit.

TwitPic.com (allows you to share photos on Twitter).

What is Twitter?, Tweeternet.com

	Paul Cacciatore on About
	Building a Team for… on About
	Kathleen on About
	Paul Cacciatore on About
	Liz on About
	Paul Cacciatore on Dana Farber Webchat: The Lates…
	Judith Marengere on Dana Farber Webchat: The Lates…
	Paul Cacciatore on Dana Farber Webchat: The Lates…
	Franca Pichini on Dana Farber Webchat: The Lates…
	painspeaks on SU2C Announces the Formation o…
	marcy westerling on SU2C Announces the Formation o…
	anne on Dana-Farber Oncologists Differ…
	Personalized Medicin… on 2011 ASCO: Matching Targeted T…
	YoTrip Presents: Sep… on U.S. President Barack Obama Pr…
	Paul Cacciatore on U.S. President Barack Obama Pr…

Libby's HOPE

HelpingOvarian Cancer SurvivorsPersevere ThroughEducation

Tag Archives: Libby’s HOPE

World Ovarian Cancer Day: Together We’re Stronger

World Ovarian Cancer Day: One Voice for Every Woman

Inaugural World Ovarian Cancer Day: “World Embrace” to Learn, Educate, Fight & Inspire

U.S. President Barack Obama Proclaims September 2011 As National Ovarian Cancer Awareness Month — What Should You Know?

The Mirror: “What is the Meaning of Life?”

2011 ASCO: Additional Phase III Study Data Support the Potential Role of Avastin in Newly-Diagnosed & Recurrent Ovarian Cancer

Libby’s HOPE & Women’s Oncology Research & Dialogue Launch New “WORD of HOPE™” Ovarian Cancer Educational Podcast Series

Libby’s HOPE™ National Ovarian Cancer Coalition 6th Annual Women’s Health Expo Presentation

Libby’s HOPE to Present At NOCC 6th Annual Women’s Health Expo (REJUVENATE Finding Balance)

Meet Laurey Masterton, 20-Year Ovarian Cancer Survivor Extraordinaire

Do You Twitter? Tell Libby’s HOPE What You’re Doing!

Twitter in Plain English

*Helping*Ovarian Cancer Survivors*Persevere Through*Education

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

Twitter in Plain English

Share this:

Like this:

HelpingOvarian Cancer SurvivorsPersevere ThroughEducation